MEMBER SPACE Login

"In accordance with the General European Regulation on the protection of individuals with regard to the processing of personal data and on the free movement of such data (RGPD) and the "Data Protection Act" of 6 January 1978 as amended, you have the right to access, rectify, oppose, delete (or "right to oblivion") or limit the processing of your personal data. You also have the right to withdraw your consent at any time by contacting XXXX . Finally, you have the possibility to lodge a complaint with a supervisory authority".

News & Highlights

News First patient in the A2 cohort of the PDC*line Pharma Phase I/II trial at our Clinical Research Center 08 October 2020

PDC*line Pharma recently announced that two new patient cohorts have been opened in the Phase I/II clinical trial PDC-LUNG-101 for its therapeutic vaccine candidate PDC*lung01 in non-small cell lung cancer (NSCLC) (NCT03970746). PDC*line Pharma is a biotechnology company developing a new class of novel, potent and easily industrialized active anti-cancer immunotherapies.

The first patient having received the drug candidate PDC*lung01 in monotherapy at “high dose” is under the supervision of Pr. Jaafar Bennouna, medical oncologist at the CHU of Nantes.

PDC*lung01 is a cell suspension composed of a mixture of seven active ingredients in identical proportions. Each is made up of irradiated human plasmacytoid dendritic cells (PDC*line) loaded with a different synthetic peptide restricted to the HLA-A*02:01 serotype, derived from tumor antigens.

PDC*line is a powerful antigen-presenting cell system that is able of priming and stimulating anti-tumor-specific cytotoxic CD8+ T cells from the patient’s immune system.

The objectives of this phase I/II trial (PDC-LUNG-101) are to evaluate the safety, tolerability, immunogenicity and preliminary clinical activity of the PDC*lung01 drug candidate, whether or not combined with anti-PD-1 therapy in NSCLC.

 

Pr Jaafar Bennouna, Medical oncologist, Pneumology unit, CHU de Nantes

« The Nantes University Hospital is very active in this clinical trial. We are pleased to have started the administration of the first patient in the A2 cohort of the PDC*line Pharma Phase I/II trial at our clinical research center,” said the Prof. Jaafar Bennouna, medical oncologist at the CHU de Nantes (France)”.

 

 

 
All the news